Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in melanoma, dashing its hopes of moving the drug earlier in the treatment pathway.

The most common areas for cancer to progress are usually the liver or lungs. Although LDH is not specific to melanoma, it can be a useful test for diagnosing or monitoring skin cancer post-surgical ...